Lipids are an important source of chemical modification of tissue proteins, even in the absence of hyperglycemia. PM inhibited AGE/ALE formation and hyperlipidemia and protected against renal and vascular pathology in a nondiabetic model.
Aims/hypothesis. This study was designed to determine whether inhibition of formation of AGE and advanced lipoxidation end-products (ALE) is a mechanism of action common to a diverse group of therapeutic agents that limit the progress of diabetic nephropathy. We compared the effects of the ACE inhibitor enalapril, the antioxidant vitamin E, the thiol compound lipoic acid, and the AGE/ALE inhibitor pyridoxamine on the formation of AGE/ALE and protection against nephropathy in streptozotocin diabetic rats. Methods. Renal function and AGE/ALE formation were evaluated in rats treated with the agents listed above. Plasma was monitored monthly for triglycerides, cholesterol, creatinine and TNF-α, and 24-h urine samples were collected for measurement of albumin and total protein excretion. After 29 weeks, renal expression of mRNA for extracellular matrix proteins was measured, and AGE/ALE were quantified in skin and glomerular and tubular collagen. Results. Diabetic animals were both hyperglycaemic and dyslipidaemic, and showed evidence of early nephropathy (albuminuria, creatinaemia). All interventions limited the progression of nephropathy, without affecting glycaemia. The order of efficacy was: pyridoxamine (650 mg·kg −1 ·day −1 ) > vitamin E (200 mg·kg −1 ·day −1 ) > lipoic acid (93 mg·kg −1 ·day −1 ) enalapril (35 mg·kg −1 ·day −1 ). Pyridoxamine also significantly inhibited AGE/ALE accumulation in tissues; effects of other agents were mixed, but the degree of renoprotection was consistent with their effects on AGE/ALE formation. Conclusions/interpretation. All interventions inhibited the progression of nephropathy at the doses studied, but the maximal benefit was achieved with pyridoxamine, which also limited dyslipidaemia and AGE/ALE formation. These experiments indicate that the more effective the renoprotection, the greater the inhibition of AGE/ALE formation. For optimal protection of renal function, it would be beneficial to select drugs whose mechanism of action includes inhibition of AGE/ALE formation.
Insulin resistance contributes to several disorders including type 2 diabetes and cardiovascular diseases. Carpachromene is a natural active compound that inhibits α-glucosidase enzyme. The aim of the present study is to investigate the potential activity of carpachromene on glucose consumption, metabolism and insulin signalling in a HepG2 cells insulin resistant model. A HepG2 insulin resistant cell model (HepG2/IRM) was established. Cell viability assay of HepG2/IRM cells was performed after carpachromene/metformin treatment. Glucose concentration and glycogen content were determined. Western blot analysis of insulin receptor, IRS1, IRS2, PI3k, Akt, GSK3, FoxO1 proteins after carpachromene treatment was performed. Phosphoenolpyruvate carboxykinase (PEPCK) and hexokinase (HK) enzymes activity was also estimated. Viability of HepG2/IRM cells was over 90% after carpachromene treatment at concentrations 6.3, 10, and 20 µg/mL. Treatment of HepG2/IRM cells with carpachromene decreased glucose concentration in a concentration- and time-dependant manner. In addition, carpachromene increased glycogen content of HepG2/IRM cells. Moreover, carpachromene treatment of HepG2/IRM cells significantly increased the expression of phosphorylated/total ratios of IR, IRS1, PI3K, Akt, GSK3, and FoxO1 proteins. Furthermore, PEPCK enzyme activity was significantly decreased, and HK enzyme activity was significantly increased after carpachromene treatment. The present study examined, for the first time, the potential antidiabetic activity of carpachromene on a biochemical and molecular basis. It increased the expression ratio of insulin receptor and IRS1 which further phosphorylated/activated PI3K/Akt pathway and phosphorylated/inhibited GSK3 and FoxO1 proteins. Our findings revealed that carpachromene showed central molecular regulation of glucose metabolism and insulin signalling via IR/IRS1/ PI3K/Akt/GSK3/FoxO1 pathway.
Inflammation is a critical defensive mechanism mainly arising due to the production of prostaglandins via cyclooxygenase enzymes. This study aimed to examine the anti-inflammatory activity of fatty acid glucoside (FAG), which is isolated from Ficus benghalensis against lipopolysaccharide (LPS)-stimulated RAW 264.7 macrophages. The cytotoxic activity of the FAG on RAW 264.7 macrophages was evaluated with an MTT assay. The levels of PGE2 and NO and the activity of iNOS, COX-1, and COX-2 enzymes in LPS-stimulated RAW 264.7 cells were evaluated. The gene expression of IL-6, TNF-α, and PGE2 was investigated by qRT-PCR. The expression of epidermal growth factor receptor (EGFR), Akt, and PI3K proteins was examined using Western blotting analysis. Furthermore, molecular docking of the new FAG against EGFR was investigated. A non-cytotoxic concentration of FAG increased NO release and iNOS activity, inhibited COX-1 and COX-2 activities, and reduced PGE2 levels in LPS-stimulated RAW 264.7 cells. It diminished the expression of TNF-α, IL-6, PGE2, EGFR, Akt, and PI3K. Furthermore, the molecular docking study proposed the potential direct binding of FAG with EGFR with a high affinity. This study showed that FAG is a natural EGFR inhibitor, NO-releasing, and COX-inhibiting anti-inflammatory agent via EGFR/Akt/PI3K pathway inhibition.
Background: Cushing syndrome is predisposed to hepatocellular disease due to increased visceral fat resulting in NAFLD, and direct effects of medical therapy, notably ketoconazole. Mifepristone (MIFE) (a competitive glucocorticoid receptor antagonist) is a CYP3A4 inhibitor, whereas loestrin (an oral contraceptive) is a CYP3A4 substrate. Recently, MIFE has been shown to improve liver enzymes in a patient with NAFLD and cortisol-secreting adrenal adenoma (Ragucci E, et al. Case Rep Endocrinol. 2017). Herein, we present a case of high-dose MIFE with loestrin in inducing cholestatic hepatitis that resolved spontaneously upon drug discontinuation. Case: A 35 year-old woman with Cushing disease (CD) underwent transsphenoidal surgery (TSS) twice (April 2014 and November 2017). Upon re-testing in January 2018, persistent hypercortisolemia was confirmed with 24-hr UFCs x 2 and late-night salivary cortisols x 2 that were > 2 ULN, and nonsuppressed AM cortisol after a 1 mg overnight dexamethasone suppression test. The patient declined pasireotide and ketoconazole due concerns of hyperglycemia and potential liver toxicity, respectively. After her first TSS, she developed secondary hypothyroidism, secondary hypogonadism and DI, and was placed on levothyroxine, loestrin and DDAVP. She agreed to consider MIFE therapy in February 2018. Baseline serum potassium and LFTs were normal, and she was initiated on MIFE 300 mg/d. Her dose was escalated to 600 mg/d in March 2018, 900 mg/d in May 2018, and alternating 900 mg/d and 1200 mg/d in June 2018. Fourteen days after being on alternating high-dose MIFE therapy, the patient presented to the ER with abdominal pains, nausea, vomiting, pruritus, jaundice and dark urine, and abnormal LFTs (hyperbilirubinemia, and mild increases in AST and ALP). She was hospitalized, and ultrasound of her abdomen revealed normal liver architecture, whereas liver biopsy confirmed diffuse canalicular and cytoplasmic bile stasis without zonal predilection consistent with acute drug-induced cholestasis. She had not taken any new medications or supplements after MIFE was initiated. Other causes of liver dysfunction were excluded including normal anti-ANA, anti-Sm and anti-mitochondrial antibodies, and normal viral hepatitis screen. She was treated symptomatically for her pruritus, MIFE and loestrin were discontinued, and she was discharged from hospital after 3 days. Her pruritus resolved and LFTs normalized 5 and 11 weeks, respectively, post-discharge. Conclusion: We report the first case of high-dose MIFE with loestrin in inducing reversible cholestatic hepatitis in CD, which contrasts to the direct hepatocellular toxicity induced by ketoconazole. Our case highlights the importance of knowledge of drugs that behave as CYP3A4 substrates or inhibitors, and close monitoring of LFTs, especially when MIFE dosing is escalated in combination with oral contraceptives.
Introduction: Chronic lymphocytic leukemia (CLL) is one of the most common leukemia in adults and elderly worldwide. It is a heterogeneous disease with variable clinical pattern and evolution. It is characterized by the clonal expansion and accumulation of neoplastic B lymphocytes expressing CD5, CD19, CD20 and CD23 in the bone marrow, peripheral blood and often the lymph nodes. Aim of the work: Assessment of expression of IL-22 in patients with chronic lymphocytic leukemia. Study expression of CD38 in patients with chronic lymphocytic leukemia. Correlate both parameters with each other and with clinical and laboratory data studied. Subjects and Methods: The present study was carried out at
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.